

Acamprosate calcium

Section

Medicines for alcohol use disorders
Oral > Solid > tablet: 333 mg

Indications

Disorders due to use of alcohol

Amitriptyline

Section

Medicines for depressive disorders
Oral > Solid: 25 mg; 75 mg

Indications

Depressive disorders

Aripiprazole

Section

Medicines for psychotic disorders
Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension

Indications

Therapeutic equivalent to risperidone pour

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to paliperidone pour

Schizophrenia or other primary psychotic disorders

Brexpiprazole

Section

Medicines for depressive disorders
Oral > Solid > tablet: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg

Indications

Depressive disorders

Buprenorphine

Section

Medicines for opioid use disorders

Indications

Therapeutic equivalent to methadone pour

Opioid dependence

Bupropion

Section

Medicines for nicotine use disorders
Oral > Solid: 150 mg sustained-release (hydrochloride)

Indications

Nicotine dependence

Carbamazepine

Section

Medicines for bipolar disorders

Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg

Indications

Bipolar or related disorders

Chlorpromazine

Section

Medicines for psychotic disorders

Oral > Liquid: 25 mg per 5 mL (hydrochloride)

Oral > Solid: 100 mg (hydrochloride)

Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Therapeutic equivalent to haloperidol pour

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Clomipramine

Section

Medicines for obsessive compulsive disorders

Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Obsessive-compulsive disorder

Clozapine

Section

Medicines for psychotic disorders

Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg

Indications

Schizophrenia or other primary psychotic disorders

Cytisine (cytisinicline)

Section

Medicines for nicotine use disorders

Oral > Solid > tablet: 1.5 mg

Indications

Nicotine dependence

Diazepam

Section

Medicines for anxiety disorders

Oral > Solid: 5 mg (scored); 2 mg (scored)

Indications

Anxiety

Fluoxetine

Section

Medicines for depressive disorders

Oral > Solid: 20 mg (as hydrochloride)

Medicines for anxiety disorders

Oral > Solid: 20 mg (as hydrochloride)

Medicines for obsessive compulsive disorders

Oral > Solid: 20 mg (as hydrochloride)

Indications

Depressive disorders

Social anxiety disorder

Generalised anxiety disorder

Panic disorder

Obsessive-compulsive disorder

Fluphenazine

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthatate)

Indications

Schizophrenia or other primary psychotic disorders

Haloperidol

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 5 mg per mL in ampoule

Oral > Solid: 2 mg; 5 mg

Indications

Schizophrenia or other primary psychotic disorders

Haloperidol decanoate

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to fluphenazine pour

Schizophrenia or other primary psychotic disorders

Lithium carbonate

Section

Medicines for bipolar disorders

Oral > Solid: 300 mg

Indications

Bipolar or related disorders

Lorazepam

Section

Medicines for anxiety disorders

Indications

Therapeutic equivalent to **diazepam** pour

Anxiety

Methadone

Section

Medicines for opioid use disorders

Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Indications

Opioid dependence

Methylphenidate

Section

Medicines for mental and behavioural disorders

Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 20 mg (hydrochloride); 18 mg extended-release (hydrochloride); 27 mg extended-release (hydrochloride); 36 mg extended-release (hydrochloride); 54 mg extended-release (hydrochloride); 72 mg extended-release (hydrochloride)

Oral > Solid > capsule: 10 to 60 mg extended-release (hydrochloride)

Indications

Attention deficit hyperactivity disorder

Naltrexone

Section

Medicines for alcohol use disorders

Parenteral > General injections > IM: 380 mg in vial (extended-release)

Oral > Solid > tablet: 50 mg

Indications

Disorders due to use of alcohol

Nicotine replacement therapy

Section

Medicines for nicotine use disorders

Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour

Oral > Solid > lozenge: 2 mg; 4 mg lozenge

Local > Buccal > Oral spray: 1 mg per actuation

Local > Buccal > Chewing gum: 2 mg; 4 mg

Indications

Nicotine dependence

Olanzapine

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 10 mg in vial powder for injection

Indications

Therapeutic equivalent to risperidone pour

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Paliperidone

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)

Indications

Therapeutic equivalent to risperidone pour

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Phenelzine

Section

Medicines for depressive disorders

Oral > Solid > dosage form: 15 mg (as sulfate)

Indications

Other specified depressive disorders

Quetiapine

Section

Medicines for psychotic disorders

Medicines for bipolar disorders

Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)

Indications

Therapeutic equivalent to risperidone pour

Schizophrenia or other primary psychotic disorders

Bipolar or related disorders

Risperidone

Section

Medicines for psychotic disorders

Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg

Parenteral > General injections > IM:

Indications

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to paliperidone pour

Schizophrenia or other primary psychotic disorders

Valproic acid (sodium valproate)

Section

Medicines for bipolar disorders

Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)

Indications

Bipolar or related disorders

Varenicline

Section

Medicines for nicotine use disorders

Oral > Solid: 0.5 mg; 1 mg

Indications

Nicotine dependence

Zuclopenthixol decanoate

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to fluphenazine pour

Schizophrenia or other primary psychotic disorders